These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 34234349)
21. Ca2+ controls gating of voltage-gated calcium channels by releasing the β2e subunit from the plasma membrane. Kim DI; Kweon HJ; Park Y; Jang DJ; Suh BC Sci Signal; 2016 Jul; 9(435):ra67. PubMed ID: 27382026 [TBL] [Abstract][Full Text] [Related]
22. Characterization of the triazine, T4, a representative from a novel series of CaV2 inhibitors with strong state-dependence, poor use-dependence, and distinctively fast kinetics. Swensen AM; Niforatos W; Lee CH; Jarvis MF; McGaraughty S Eur J Pharmacol; 2014 Dec; 745():234-42. PubMed ID: 25446431 [TBL] [Abstract][Full Text] [Related]
23. The calcium channel alpha2delta-2 subunit partitions with CaV2.1 into lipid rafts in cerebellum: implications for localization and function. Davies A; Douglas L; Hendrich J; Wratten J; Tran Van Minh A; Foucault I; Koch D; Pratt WS; Saibil HR; Dolphin AC J Neurosci; 2006 Aug; 26(34):8748-57. PubMed ID: 16928863 [TBL] [Abstract][Full Text] [Related]
24. Novel analgesic ω-conotoxins from the vermivorous cone snail Conus moncuri provide new insights into the evolution of conopeptides. Sousa SR; McArthur JR; Brust A; Bhola RF; Rosengren KJ; Ragnarsson L; Dutertre S; Alewood PF; Christie MJ; Adams DJ; Vetter I; Lewis RJ Sci Rep; 2018 Sep; 8(1):13397. PubMed ID: 30194442 [TBL] [Abstract][Full Text] [Related]
25. Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy. Khanna R; Yu J; Yang X; Moutal A; Chefdeville A; Gokhale V; Shuja Z; Chew LA; Bellampalli SS; Luo S; François-Moutal L; Serafini MJ; Ha T; Perez-Miller S; Park KD; Patwardhan AM; Streicher JM; Colecraft HM; Khanna M Pain; 2019 Jul; 160(7):1644-1661. PubMed ID: 30933958 [TBL] [Abstract][Full Text] [Related]
26. Neurobehavioral protection by the neuronal calcium channel blocker ziconotide in a model of traumatic diffuse brain injury in rats. Berman RF; Verweij BH; Muizelaar JP J Neurosurg; 2000 Nov; 93(5):821-8. PubMed ID: 11059664 [TBL] [Abstract][Full Text] [Related]
27. α-Neurexins Together with α2δ-1 Auxiliary Subunits Regulate Ca Brockhaus J; Schreitmüller M; Repetto D; Klatt O; Reissner C; Elmslie K; Heine M; Missler M J Neurosci; 2018 Sep; 38(38):8277-8294. PubMed ID: 30104341 [TBL] [Abstract][Full Text] [Related]
28. Voltage-dependent G-protein regulation of Ca Nilsson M; Wang K; Mínguez-Viñas T; Angelini M; Berglund S; Olcese R; Pantazis A Sci Adv; 2024 Sep; 10(37):eadp6665. PubMed ID: 39259796 [TBL] [Abstract][Full Text] [Related]
29. Voltage-dependent regulation of CaV2.2 channels by Gq-coupled receptor is facilitated by membrane-localized β subunit. Keum D; Baek C; Kim DI; Kweon HJ; Suh BC J Gen Physiol; 2014 Oct; 144(4):297-309. PubMed ID: 25225550 [TBL] [Abstract][Full Text] [Related]
30. Altered synaptic transmission at olfactory and vomeronasal nerve terminals in mice lacking N-type calcium channel Cav2.2. Weiss J; Pyrski M; Weissgerber P; Zufall F Eur J Neurosci; 2014 Nov; 40(10):3422-35. PubMed ID: 25195871 [TBL] [Abstract][Full Text] [Related]
31. ZC88, a novel N-type calcium channel blocker from 4-amino-piperidine derivatives state-dependent inhibits Cav2.2 calcium channels. Zhang S; Yang L; Zhang K; Liu X; Dai W; Zhang C; Yong Z; Li J; Zheng J Brain Res; 2015 Apr; 1605():12-21. PubMed ID: 25681549 [TBL] [Abstract][Full Text] [Related]
32. Alternative splicing of a beta4 subunit proline-rich motif regulates voltage-dependent gating and toxin block of Cav2.1 Ca2+ channels. Helton TD; Kojetin DJ; Cavanagh J; Horne WA J Neurosci; 2002 Nov; 22(21):9331-9. PubMed ID: 12417658 [TBL] [Abstract][Full Text] [Related]
33. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Miljanich GP Curr Med Chem; 2004 Dec; 11(23):3029-40. PubMed ID: 15578997 [TBL] [Abstract][Full Text] [Related]
34. Design, Synthesis and Biological Evaluation of Two Opioid Agonist and Cav 2.2 Blocker Multitarget Ligands. Mollica A; Costante R; Novellino E; Stefanucci A; Pieretti S; Zador F; Samavati R; Borsodi A; Benyhe S; Vetter I; Lewis RJ Chem Biol Drug Des; 2015 Aug; 86(2):156-62. PubMed ID: 25393330 [TBL] [Abstract][Full Text] [Related]
35. Development of small molecules that mimic the binding of omega-conotoxins at the N-type voltage-gated calcium channel. Schroeder CI; Smythe ML; Lewis RJ Mol Divers; 2004; 8(2):127-34. PubMed ID: 15209164 [TBL] [Abstract][Full Text] [Related]
36. Antidepressant-like and memory-enhancing effects of the N-type calcium channel blocker ziconotide in rats. Bozorgi H; Budde T; Nankali M Behav Brain Res; 2020 Jul; 390():112647. PubMed ID: 32428635 [TBL] [Abstract][Full Text] [Related]
37. Translocatable voltage-gated Ca Yeon JH; Park CG; Hille B; Suh BC Proc Natl Acad Sci U S A; 2018 Oct; 115(42):E9934-E9943. PubMed ID: 30257950 [TBL] [Abstract][Full Text] [Related]
38. Complex structures between the N-type calcium channel (CaV2.2) and ω-conotoxin GVIA predicted via molecular dynamics. Chen R; Chung SH Biochemistry; 2013 May; 52(21):3765-72. PubMed ID: 23651160 [TBL] [Abstract][Full Text] [Related]
39. Analgesic effect of highly reversible ω-conotoxin FVIA on N type Ca2+ channels. Lee S; Kim Y; Back SK; Choi HW; Lee JY; Jung HH; Ryu JH; Suh HW; Na HS; Kim HJ; Rhim H; Kim JI Mol Pain; 2010 Dec; 6():97. PubMed ID: 21172037 [TBL] [Abstract][Full Text] [Related]
40. Improvement in mitochondrial dysfunction as a new surrogate efficiency measure for preclinical trials: dose-response and time-window profiles for administration of the calcium channel blocker Ziconotide in experimental brain injury. Verweij BH; Muizelaar JP; Vinas FC; Peterson PL; Xiong Y; Lee CP J Neurosurg; 2000 Nov; 93(5):829-34. PubMed ID: 11059665 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]